Approaches to cancer therapy using biological response modifiers.
E G
EG
MacEwen
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use; D001428:Bacterial Vaccines / Q000627:therapeutic use; D001798:Blood Proteins / Q000627:therapeutic use; D002371:Cat Diseases / Q000628:therapy*; D002415:Cats; D002473:Cell Wall; D004283:Dog Diseases / Q000628:therapy*; D004285:Dogs; D007167:Immunotherapy; D007369:Interferon Inducers / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D008081:Liposomes / Q000008:administration & dosage; D008222:Lymphokines / Q000627:therapeutic use; D009369:Neoplasms / Q000628:therapy / Q000662:veterinary*; D013205:Staphylococcal Protein A / Q000627:therapeutic use; D014405:Tuftsin / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D001500:BCG Vaccine; D001428:Bacterial Vaccines; D001798:Blood Proteins; D007369:Interferon Inducers; D008081:Liposomes; D008222:Lymphokines; D013205:Staphylococcal Protein A; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D007372:Interferons; D014405:Tuftsin